Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages

Cancer

Volumn 95, Issue 9, 2002, Pages 2032-2037

  Shapiro, Sarah ^a   Shoenfeld, Yehuda ^b   Gilburd, Boris ^b,c   Sobel, Esther ^a   Lahat, Nitza ^a,d  

^a CARMEL MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Gamma globulin; IVIG; Macrophages; MMP 9; TNF

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; OMRIGAM;

ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NORTHERN BLOTTING; PRIORITY JOURNAL; ZYMOGRAPHY;

BLOTTING, NORTHERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MONOCYTES; RNA, MESSENGER;

EID: 0036840967     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10905     Document Type: Article

References (20)

1. Nagase H. Matrix metalloproteinases. In: Hooper NM, editor. Zinc Metalloproteinases in Health and Disease. London: Taylor & Francis, 1996:153-204.
2. Borden P, Heller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Expression. 1997;7:159-178.
3. Zucker S, Cao J. Imaging metalloproteinase activity in vivo. Nature Med. 2001;7:655-656.
4. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest. 1999;103:1237-1241.
5. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999;13:35-48.
6. Yu Q, Stamenkovic I. Cell surface-localiβzed matrix metalloproteinase 9 proteolytically activates TGF-B and promotes tumor invasion. Genes Dev. 1999;13:35-48.
7. USA Patent No 5,562,902. Immunotherapeutic Method of Treating Cancerous Diseases by Administration of Intravenous Immunoglobulin. Shoenfeld et al 1996.
8. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune mediated diseases. Clin Exp Immunol. 1996;104S:13-19.
9. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol. 1999;11:1247-1251.
10. Carmeli Y, Mevorach D, Kaminski N, Raz E. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment of polymyositis. Cancer. 1994;73:2859-2863.
11. Senzaki H, Masutani S, Kobayashi J, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation. 2001;104:860-863.
12. Ronda N, Leonardi S, Orlandini G, et al. Natural anti-endothelial cell antibodies (AECA). J Autoimmun. 1999;13:121-127.
13. Sitrin RG, Pan PM, Srikanth S, Todd RF. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol. 1998;161:1462-1470.
14. Xie B, Laouar A, Huberman E. Autocrine regulation of macrophage differentiation and 92-kDa production by tumor necrosis factor-α via α5B1 integrin in HL-60 cells. J Biol Chem. 1998;19:11583-11588.
15. Vos CM, Gartner S, Ransohoff RM, et al. Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: Implications for neuroinflammation and neurodegeneration. J Neuroimmunol. 2000;109:221-227.
16. Nemes E, Teichman F, Roos D, Marodi L. Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcgammaRII and FcgammaRIII receptors. Pediatr Res. 2000;47:357-361.
17. Bar-Dayan Y, Barshack I, Blank M, et al. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int J Oncol. 1999;15:1091-1096.
18. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity, of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
19. Darville T, Milligan LB, Laffoon KK. Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun. 1997;65:366-372.
20. Vassilev TL, Kazatchkine MD, Van Huyen JPD, et al. Inhibition of cell adhesion antibodies to arg-gly-asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIG). Blood. 1999;93:3624-3631.